GHO Capital Acquires U.K.-based Quotient Clinical

December 7, 2015

Applied Clinical Trials

Quotient Clinical is based in Nottingham, U.K., where formulation development, real-time Good Manufacturing Practice services, and early clinical trials are performed at the same facility.

Quotient Clinical, a provider of early stage and drug development services, has been acquired by healthcare investor GHO Capital.

Quotient Clinical is based in Nottingham, U.K., where formulation development, real-time Good Manufacturing Practice services, and early clinical trials are performed at the same facility. It employs over 280 staff and offers a range of support services, from study set-up to data analysis and reporting. Over 75% of its customers are in the U.S. or mainland Europe.

“We are delighted to be partnering with GHO Capital for the next phase of our growth,” said Mark Egerton, Chief Executive Officer of Quotient Clinical. “In the past few years, we have proven the benefits of Translational Pharmaceutics (the company’s own platform), and its adoption by an ever increasing number of customers continues to drive our business growth. Partnering with GHO Capital, we will now work to expand our differentiated service portfolio and extend our operational footprint internationally.”
 

Read the full release.